Brain

IRLAB Publishes Interim Report for the Period January – September 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / October 30, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company…

1 year ago

3X4 Genetics and Fullscript Announce next step in Partnership to Enhance Whole Person Care Through Genetic Insights

BELLEVUE, Wash., Oct. 29, 2024 /PRNewswire/ -- 3X4 Genetics, a pioneer in functional nutrigenomics, is thrilled to announce the next step…

1 year ago

QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson’s Disease

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- QuantalX Neuroscience, a leader in objective neurodiagnostic technology, announces a significant discovery in the…

1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase…

1 year ago

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

1 year ago

Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development

CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial…

1 year ago

Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy

LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA)…

1 year ago

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and…

1 year ago

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

1 year ago

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics…

1 year ago